10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.
How this was made
The 30-second read
Why it matters
Guidance raise and consumables momentum provide a catalyst for continued rally, but valuation and instrument weakness pose risks.
Market read
Guidance update and growth metrics are material for traders tracking biotech equities and the genomics sector.
What to watch
Capacity constraints for Atera ramp and potential funding environment changes could limit growth.
Background
10x Genomics reported Q2 2026 results, showing consumables revenue growth, weak instrument sales, and an updated revenue outlook.
Ticker impact
TXG raised its 2026 revenue guidance to $610M-$630M, up from $600M-$625M, and reported consumables growth and instrument weakness.
Potential further upside if consumables growth sustains; downside risk if instrument sales remain weak.
Guidance is a primary disclosure with material numbers; market will price in higher expectations, but elevated valuation limits upside.
Market effects
Highlights strength of consumables in genomics sector versus instrument sales, may benefit peers with similar models.
U.S. biotech market sees mixed signals; guidance lift may boost sector sentiment.
Limited to genomics and biotech investors globally.
Counterpoint
Valuation premium may be unjustified given persistent instrument losses and high operating losses.
Key entities
- company10x Genomics, Inc.
Subject of the article; biotech firm providing single-cell and spatial genomics solutions.
